Korro Bio, Inc. Lease, Cost
Korro Bio, Inc. (KRRO) reported Lease, Cost of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Korro Bio, Inc. lease, cost for the quarter ending 2026-06-30 was $2.08M, a 0.58% increase year-over-year.
- Korro Bio, Inc. lease, cost for the quarter ending 2026-03-31 was $2.14M, a 1.29% decline year-over-year.
- Korro Bio, Inc. lease, cost for the quarter ending 2025-12-31 was $2.02M, a 1.21% increase year-over-year.
- Korro Bio, Inc. lease, cost for the quarter ending 2025-09-30 was $2.03M, a 23.85% decline year-over-year.
- Korro Bio, Inc. lease, cost for fiscal 2025 was $8.29M, a 20.35% decline from fiscal 2024.
- Korro Bio, Inc. lease, cost for fiscal 2024 was $10.40M, a 28.74% increase from fiscal 2023.
- Korro Bio, Inc. lease, cost for fiscal 2023 was $8.08M, a 166.40% increase from fiscal 2022.
- Korro Bio, Inc. lease, cost for fiscal 2022 was $3.03M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-06 | $4.22M 10-Q · filed 2026-08-06 | $6.24M derived: sum of 3 quarters · filed 2026-08-06 | $8.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.14M 10-Q · filed 2026-05-07 | $4.16M derived: sum of 2 quarters · filed 2026-05-07 | $6.19M derived: sum of 3 quarters · filed 2026-05-07 | $8.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.05M derived: sum of 2 quarters · filed 2026-03-12 | $6.12M derived: sum of 3 quarters · filed 2026-08-06 | $8.29M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.03M 10-Q · filed 2025-11-12 | $4.10M derived: sum of 2 quarters · filed 2026-08-06 | $6.27M 10-Q · filed 2025-11-12 | $8.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.07M 10-Q · filed 2026-08-06 | $4.24M 10-Q · filed 2026-08-06 | $6.23M derived: sum of 3 quarters · filed 2026-08-06 | $8.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.17M 10-Q · filed 2026-05-07 | $4.16M derived: sum of 2 quarters · filed 2026-05-07 | $6.83M derived: sum of 3 quarters · filed 2026-05-07 | $9.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.66M derived: sum of 2 quarters · filed 2026-03-12 | $7.48M derived: sum of 3 quarters · filed 2026-03-12 | $10.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.67M 10-Q · filed 2025-11-12 | $5.49M derived: sum of 2 quarters · filed 2025-11-12 | $8.41M 10-Q · filed 2025-11-12 | $11.41M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.83M 10-Q · filed 2025-08-12 | $5.75M 10-Q · filed 2025-08-12 | $8.75M derived: sum of 3 quarters · filed 2025-08-12 | $11.07M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.92M 10-Q · filed 2025-05-07 | $5.92M derived: sum of 2 quarters · filed 2025-05-07 | $8.25M derived: sum of 3 quarters · filed 2025-05-07 | $10.08M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $5.33M derived: sum of 2 quarters · filed 2025-03-18 | $7.16M derived: sum of 3 quarters · filed 2025-03-18 | $8.08M 10-K · filed 2025-03-18 |
| 2023-09-30 | $2.33M 10-Q · filed 2024-11-12 | $4.16M derived: sum of 2 quarters · filed 2024-11-12 | $5.08M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.83M 10-Q · filed 2024-08-13 | $2.75M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $920.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $3.03M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |